

A study of genetic and environmental factors associated with kidney disease in people of African ancestry living in the UK

Submission date 04/05/2022	Recruitment status Recruiting	<input checked="" type="checkbox"/> Prospectively registered
		<input checked="" type="checkbox"/> Protocol
Registration date 05/05/2022	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 06/01/2026	Condition category Urological and Genital Diseases	<input type="checkbox"/> Individual participant data
		<input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

People of African or Afro-Caribbean ancestry are five times more likely to have kidney disease. They also develop kidney failure when they are about 10 years younger than white people. The connection between ethnicity and kidney disease is complex.

A gene pattern (APOL1-G1/G2 alleles) has been found which is common in people of African and Afro-Caribbean ancestry. We think this gene pattern prevents some forms of sleeping sickness which is why so many people of West African and Afro-Caribbean ancestry have these gene patterns. This gene pattern may make it more likely for some people to develop kidney disease (including particular types of disease: focal segmental glomerulosclerosis (FSGS), hypertensive-associated kidney disease). We do not completely understand why some people with these gene patterns develop kidney disease while others do not. We think there are additional factors including extra genetic changes and/or environmental triggers e.g. infection which lead to onset of kidney disease.

We would like to test your blood, urine and kidney tissue (if you have previously had a kidney biopsy) to get more information. This will allow us to develop tests to predict who is going to have kidney damage and find ways to prevent damage. You do not need to have a kidney biopsy if you have not already had one as part of your clinical care.

Who can participate?

For CKD Group:

You are of African or Afro-Caribbean ancestry and have kidney disease. This means that either your kidneys work less well than expected or that your kidneys leak protein or blood into your urine.

For Control Group:

You are of African or Afro-Caribbean ancestry and DO NOT have kidney disease

What does the study involve?

You will see one of the doctors or nurses who will answer any questions that you may have. If you agree to take part, we will ask you to sign a consent form and you will be given a copy to keep. We will then take extra blood, and urine from you. We will take a minimum of one extra

blood test from you and we will try to do these tests when you attend your normal appointments so you will not have any extra visits to the hospital or extra needles. We will take no more than 40 ml of blood from you at one point (4 tablespoons). There will be no repeat blood tests after this. We will also look at relevant medical records.

If you have had a kidney biopsy we will ask for your permission to retrieve any spare tissue that is available from storage for testing. You will not be asked to have any more kidney biopsy samples taken.

What are the possible benefits and risks of participating?

Your samples and information may help us to improve the treatment of people of African or Afro-Caribbean ancestry with kidney disease in the future.

There are no risks to you by taking part. The amount of extra blood that we take will not affect you. Occasionally people experience pain or bruising from having blood taken, but we will try to do this at the same time as your routine blood tests to minimise discomfort.

Where is the study run from?

The study will be running in the Renal Unit of King's College Hospital NHS Foundation Trust (UK)

When is the study starting and how long is it expected to run for?

March 2022 to December 2027

Who is funding the study?

The study is co-sponsored by King's College Hospital NHS Foundation Trust and Kings College London and funded by AstraZeneca (UK).

Who is the main contact?

1. Dr Kate Bramham, kate.bramham@kcl.ac.uk
2. Amrita Ramnarine, amrita.ramnarine@kcl.ac.uk
3. Dalvir Kular, dalvir.kular@kcl.ac.uk

Contact information

Type(s)

Principal investigator

Contact name

Dr Kate Bramham

ORCID ID

<https://orcid.org/0000-0002-6272-7921>

Contact details

King's College Hospital NHS Foundation Trust

Renal Unit

Denmark Hill

London

United Kingdom

SE5 9RS

+44 203 299 6233

kate.bramham@kcl.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Integrated Research Application System (IRAS)

292365

Central Portfolio Management System (CPMS)

52421

Study information

Scientific Title

APolipoprotein L1 in People of African ancestry Living in the UK: Exploration of genetic and environmental factors associated with Chronic Kidney Disease (APPLE-CKD)

Acronym

APPLE-CKD

Study objectives

Primary:

To establish if epigenetic DNA methylation patterns in the APOL1 gene promoter in renal tissue are comparable to peripheral blood mononuclear cells PBMC (or spleen) and urine in participants with CKD and controls (including deceased kidney donors) with APOL1 high and low-risk genotypes

Secondary:

1. To study the role of APOL1 genetics and epigenetics in the differentiation of inducible Pluripotent Stem Cells into kidney relevant cells
2. To develop a 'clinical/genetic/epigenetic/inflammatory signature' associated with CKD in people of African ancestry with validation

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 03/05/2022, North West - Greater Manchester West Research Ethics Committee (Barlow House, 3rd Floor, 4 Minshull Street, Manchester, M1 3DZ, UK; +44 2071048007; gmwest.rec@hra.nhs.uk), ref 22/NW/0100

Study design

Multicentre observational cohort

Primary study design

Observational

Study type(s)

Other

Health condition(s) or problem(s) studied

Exploration of genetic and environmental factors associated with chronic kidney disease in patients of African ancestry

Interventions

In the study, plasma, serum, urine, pre-existing renal tissue and peripheral blood mononuclear cells (PBMC) will be collected from patients. These will be sent for further analyses for:

1. Genotyping and epigenetic analysis - for PBMC (spleen MCs), renal biopsy tissue, urine pellets cases and controls
2. APOL1 and inflammatory marker analysis - for plasma, serum, renal biopsy tissue, urine supernatant and urine pellets
3. Inducible Pluripotent Stem Cell (iPSC) analysis - for the cryopreserved PBMCs

Intervention Type

Genetic

Primary outcome(s)

At a single time point:

1. APOL1 promoter DNA methylation patterns in renal tissue and PBMC (spleen) and urine (Cases only) measured using standard laboratory analysis
2. CKD disease phenotype measured using standard laboratory analysis

Key secondary outcome(s)

At a single time point:

Clinical characteristics from patient notes and laboratory records, inflammatory markers measured using novel proteomic methods

Completion date

31/12/2027

Eligibility

Key inclusion criteria

CKD cases:

1. Self-reported African ancestry
2. Aged ≥ 18 years
3. Willing and able to provide written informed consent
4. Chronic kidney disease (KDIGO Criteria)
5. Group 1: Without diabetic nephropathy or serological or biopsy-proven evidence of immune-mediated kidney disease
6. Group 2: With diabetic nephropathy or serological or biopsy-proven evidence of immune-mediated kidney disease

Controls:

1. Self-reported African ancestry
2. Aged ≥ 18 years
3. Willing and able to provide written informed consent
4. No CKD (estimated GFR >60 ml/min/1.73m² and urinary protein: creatinine <15 mg /mol or albumin: creatinine ratio <3 mg/mmol or negative urine dip for protein).

Participant type(s)

Healthy volunteer, Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

18 years

Upper age limit

100 years

Sex

All

Total final enrolment

0

Key exclusion criteria

For both CKD cases and controls:

1. Unable to provide informed consent
2. Pregnancy

Date of first enrolment

01/06/2022

Date of final enrolment

31/12/2027

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre

King's College Hospital NHS Foundation Trust

Denmark Hill

London

England

SE5 9RS

Study participating centre

Guys Hospital
Guys Hospital
Great Maze Pond
London
England
SE1 9RT

Sponsor information

Organisation

King's College Hospital NHS Foundation Trust

ROR

<https://ror.org/01n0k5m85>

Organisation

King's College London

ROR

<https://ror.org/0220mzb33>

Funder(s)

Funder type

Industry

Funder Name

AstraZeneca

Alternative Name(s)

AstraZeneca PLC, Pearl Therapeutics, AZ

Funding Body Type

Government organisation

Funding Body Subtype

For-profit companies (industry)

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			20/09/2023	No	No
Participant information sheet	Cases version 1.1	25/04/2022	05/05/2022	No	Yes
Participant information sheet	Controls version 1.1	25/04/2022	05/05/2022	No	Yes
Protocol file	version 1.1	25/04/2022	05/05/2022	No	No